Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.
Broad pipeline of clinical and next generation programs
NG = Next generation
SCLC = Small Cell Lung Cancer
* Subject to confirmation by regulatory authorities
Lead Clinical Programs
AUTO1 is a novel investigational CD19-targeting CAR T cell therapy designed to overcome the limitations in safety - while maintaining similar levels of efficacy - compared to current CD19 CAR T cell therapies. AUTO1 has a fast target binding off-rate designed to minimize excessive activation and associated cytokine release, which may reduce toxicity. In addition, the fast off-rate may reduce T cell exhaustion, enhance persistence, and improve the programmed T cells' ability to engage in serial killing of target cancer cells. AUTO1 is Autolus’ most advanced program and recently entered a pivotal study in adult ALL and is also being evaluated in a Phase I study in pediatric ALL.
AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. It has also been designed with a safety profile suitable for all settings of care, including outpatient therapy. AUTO3 is currently being tested in a Phase I study in diffuse large B cell lymphoma.
A programmed T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1, employing a novel and differentiated treatment approach. AUTO4 is designed to selectively kill cancerous T cells in a manner that we believe will preserve a portion of the patient’s normal, healthy T cells to maintain immunity. Since the AUTO4 approach is a novel mechanism to target T cells, Autolus has also programmed the product candidate with a “safety switch” in order to allow physicians to manage toxicity by eliminating the programmed T cells if a patient experiences severe adverse side effects from the treatment. AUTO4 is currently being tested in a Phase I study in TRBC1-positive peripheral T cell lymphoma.
A programmed T cell therapy targeting GD2 in development for the treatment of neuroblastoma. A Phase 1 clinical trial with AUTO6 is being sponsored and conducted by Cancer Research UK, or CRUK, and preliminary data has shown initial anti-tumor activity in this solid tumor indication. Autolus is developing a next-generation product candidate, AUTO6NG, incorporating additional programming modules designed to improve the efficacy, safety and persistence of AUTO6 which is currently in preclinical development.